The association between increasing body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and risk of breast cancer is unique in cancer epidemiology in that a crossover effect exists, with risk reduction before and risk increase after menopause. The inverse association with premenopausal breast cancer risk is poorly characterized but might be important in the understanding of breast cancer causation.

**OBJECTIVE** To investigate the association of BMI with premenopausal breast cancer risk, in particular by age at BMI, attained age, risk factors for breast cancer, and tumor characteristics.

**DESIGN, SETTING, AND PARTICIPANTS** This multicenter analysis used pooled individual-level data from 758,592 premenopausal women from 19 prospective cohorts to estimate hazard ratios (HRs) of premenopausal breast cancer in association with BMI from ages 18 through 54 years using Cox proportional hazards regression analysis. Median follow-up was 9.3 years (interquartile range, 4.9-13.5 years) per participant, with 13,082 incident cases of breast cancer. Participants were recruited from January 1, 1963, through December 31, 2013, and data were analyzed from September 1, 2013, through December 31, 2017.

**EXPOSURES** Body mass index at ages 18 to 24, 25 to 34, 35 to 44, and 45 to 54 years.

**MAIN OUTCOMES AND MEASURES** Invasive or in situ premenopausal breast cancer.

**RESULTS** Among the 758,592 premenopausal women (median age, 40.6 years; interquartile range, 35.2-45.5 years) included in the analysis, inverse linear associations of BMI with breast cancer risk were found that were stronger for BMI at ages 18 to 24 years (HR per 5 kg/m² [5.0-U] difference, 0.77; 95% CI, 0.73-0.80) than for BMI at ages 45 to 54 years (HR per 5.0-U difference, 0.88; 95% CI, 0.86-0.91). The inverse associations were observed even among nonoverweight women. There was a 4.2-fold risk gradient between the highest and lowest BMI categories (BMI ≥ 35.0 vs <17.0) at ages 18 to 24 years (HR, 0.24; 95% CI, 0.14-0.40). Hazard ratios did not appreciably vary by attained age or between strata of other breast cancer risk factors. Associations were stronger for estrogen receptor–positive and/or progesterone receptor–positive than for hormone receptor–negative breast cancer for BMI at every age group (eg, for BMI at age 18 to 24 years: HR per 5.0-U difference for estrogen receptor–positive and progesterone receptor–positive tumors, 0.76 [95% CI, 0.70-0.81] vs hormone receptor–negative tumors, 0.85 [95% CI: 0.76-0.95]); BMI at ages 25 to 54 years was not consistently associated with triple-negative or hormone receptor–negative breast cancer overall.

**CONCLUSIONS AND RELEVANCE** The results of this study suggest that increased adiposity is associated with a reduced risk of premenopausal breast cancer at a greater magnitude than previously shown and across the entire distribution of BMI. The strongest associations of risk were observed for BMI in early adulthood. Understanding the biological mechanisms underlying these associations could have important preventive potential.
Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women

Research Original Investigation

B

reast cancer is the most commonly diagnosed cancer among women worldwide, accounting for 25% of female cancer cases at all ages and a greater percentage among young women. Its complex etiology involves an unusually large range of factors, of which adiposity, often assessed as body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), is important and appears to have opposing effects at premenopausal and postmenopausal ages.

Increased adiposity in childhood and before menopause has been reported to be inversely associated with the risk of breast cancer diagnosed at premenopausal and postmenopausal ages, whereas increased adiposity after menopause is positively associated with risk. However, because incidence rates are lower among premenopausal than postmenopausal women, individual studies have had limited ability to investigate the association of BMI with the risk of premenopausal breast cancer. Past studies have been case-control studies, with potential for bias, and most prospective studies have had modest numbers of cases, except for some recent studies in Asian12,13 or Jewish Israeli14 populations, but have not assessed risk at different ages, by tumor type, and by menopausal status at breast cancer diagnosis. Meta-analyses have aggregated studies that differed in age at BMI assessment, attained age of participants, and degree of adjustment for potential confounding, and results were not stratified by other risk factors. Some studies suggest that the association of premenopausal adiposity with risk varies by tumor characteristics, but larger studies are needed to provide stable estimates by hormone receptor status or intrinsic tumor subtype.

To undertake a more powerful and systematic analysis of the association of BMI with breast cancer risk in premenopausal women, we pooled individual-level data from 758 592 women, including 13 082 cases of breast cancer, from 19 prospective cohort studies using data from recruitment and follow-up questionnaires. We aimed to estimate the relative risk associated with BMI at different ages, age at breast cancer diagnosis, and breast cancer characteristics and to explore whether associations were modified by other risk factors for breast cancer.

Methods

Information on the Premenopausal Breast Cancer Collaborative Group, a collaboration facilitated by the National Cancer Institute Cohort Consortium, has been published previously. In short, individual-level data were pooled from 19 prospective cohorts in North America (n = 9), Europe (n = 7), Asia (n = 2), and Australia (n = 1), with participants recruited from January 1, 1963, through December 31, 2013 and at least 100 breast cancer cases diagnosed before 55 years of age. Data were harmonized to a common template for 1 to 16 questionnaire rounds per study. Full details of the study cohorts are given in the eMethods in the Supplement. All contributing studies gained approval from institutional review boards and obtained consent from participants as per country-specific requirements.

We used information on self-reported or measured current weight and height from multiple questionnaire rounds and information reported on questionnaires about weight at ages before study entry to construct BMI within the age ranges of 18 to 24, 25 to 34, 35 to 44, and 45 to 54 years. We categorized BMI according to World Health Organization definitions. The analysis included all participants who were premenopausal, had no personal history of breast cancer at study entry, and had data for premenopausal BMI available. All breast cancers included in this analysis occurred before menopause, with the main analytic end point being invasive or in situ premenopausal breast cancer overall. However, we also analyzed separately by invasive and in situ cancer, by immunohistochemistry data on estrogen receptor (ER) and progesterone receptor (PR) status, and by clinicopathologic surrogate definitions of intrinsic breast cancer subtype.

Hazard ratios (HRs) were obtained as estimates of the relative risk of breast cancer from Cox proportional hazards regression models with attained age as the underlying timescale. Follow-up for breast cancer started at study entry or the age after enrollment to which the BMI applied. Follow-up ended at breast cancer diagnosis, menopause (or hysterectomy), last follow-up, death, or age 55 years, whichever occurred first.

We first generated cohort-specific relative risk estimates and obtained a pooled estimate with a 2-stage model. Because no appreciable between-study heterogeneity was detected using the F statistic, the data were analyzed in a pooled data set. All presented analyses were adjusted for attained age (implicit in the Cox proportional hazards regression model), cohort, year of birth, age at menarche, age at first birth, time since last birth, parity, and family history of breast cancer. Covariate information was time updated, when possible, with information from follow-up questionnaires.

We analyzed BMI separately as categorical and continuous variables (per 5 kg/m² [5.0-U] difference), assuming a log-linear dose-response association, the validity of which was checked using restricted cubic spline models. We tested for effect modification by other risk factors for breast cancer and by attained age using log-likelihood ratio tests. Analyses by breast tumor subtype were conducted using an augmentation method. This method allows estimation of separate risk

Key Points

**Question** What is the association between body mass index and risk for breast cancer diagnosed before menopause?

**Finding** In this large pooled analysis of data on 758 592 premenopausal women, an inverse association of breast cancer risk with body mass index at 18 through 54 years of age was found, most strongly for body mass index at ages 18 through 24 years. The inverse association was strongest for hormone receptor–positive breast cancer, was evident across the entire distribution of body mass index, and did not materially vary by attained age or other characteristics of women.

**Meaning** Increased adiposity, in particular during early adulthood, may be associated with reductions in the risk of premenopausal breast cancer.
factor associations for type-specific outcomes in a single model stratified on outcome type, obtained from a data set in which separate observations on each participant have been created for each outcome. Conducted sensitivity analyses are outlined in the eMethods in the Supplement. We used Stata, version 14.2 (StataCorp) for all analyses, with $P < .05$ indicating significance.28

Results

The analyses included 758 592 women (median age, 40.6 years; interquartile range, 35.2-45.5 years), among whom 13 082 in situ or invasive breast cancer cases occurred during 7.2 million premenopausal years of follow-up (median, 9.3 years; interquartile range, 4.9-13.5 years) (eTable 1 in the Supplement). Weight was provided at 1 to 14 (median, 2) follow-up rounds per study and was self-reported for 88.9% to 99.6% of weights, depending on age. Weight at ages 18 to 24 years was retrospectively reported for 96.9% and at later ages for less than 10% of women. Obesity (BMI ≥ 30.0) was more common in women who were 45 years or older (11.1%), were nulliparous (12.4%), had an early menarche (17.0%), had a family history of breast cancer (12.8%), or were black (26.8%) (Table). Increasing BMI was linearly associated with decreasing risk of breast cancer in the restricted cubic spline models (eFigures 1 and 2 in the Supplement), except that, for some ages and tumor types, there appeared to be a leveling of risk for underweight women (BMI < 18.5) compared with those in the normal weight range (BMI, 18.5-24.9). We therefore restricted the linear modeling of BMI to values of 18.5 or greater.

Hazard ratios for breast cancer decreased with increasing BMI category (Figure 1), more for BMI at younger than older ages, with a risk reduction of 23% per 5.0-U difference (HR, 0.77; 95% CI, 0.73-0.80) for BMI at ages 18 to 24 years and 12% (HR, 0.88; 95% CI, 0.86-0.91) for BMI at 45 to 54 years. The risk gradient was 4.2-fold between the highest and lowest BMI categories (BMI ≥ 35.0 vs <17.0) at ages 18 to 24 years (HR, 0.24; 95% CI, 0.14-0.40). Significant differences in relative risk were present even within the normal range of BMI (for 23.0-24.9 vs 18.5-22.9: HR, 0.80; 95% CI, 0.75-0.86). The HRs for BMI at ages 18 to 24 years remained statistically significant after additional adjustment for most recent BMI (HR per 5.0-U increase, 0.80; 95% CI, 0.76-0.84). We found no appreciable heterogeneity in the association between studies (eFigure 3A-D in the Supplement).

Weight at ages 18 to 24 years was correlated with weights at older ages ($r = 0.70$ for ages 25-34, $r = 0.63$ for ages 35-44, and $r = 0.55$ for ages 45-54 years). When we adjusted the analyses of breast cancer risk in Figure 2 for BMI at ages 18 to 24 years, the HRs per 5.0-U increase were 0.92 (95% CI, 0.88-0.97) for BMI at ages 25 to 34 years, 0.93 (95% CI, 0.91-0.96) at ages 35 to 44 years, and 0.91 (95% CI, 0.88-0.93) at ages 45 to 54 years (Figure 2 and eTable 2 in the Supplement). The magnitude of the inverse associations was similar between categories of attained age to age 55 years (eFigure 4 in the Supplement).

Incident cases of breast cancer included 10 836 invasive and 2138 in situ breast cancers. Associations with risk per 5.0-U difference in BMI were significantly larger for in situ (HR, 0.76; 95% CI, 0.69-0.85) than for invasive breast cancer (HR, 0.88; 95% CI, 0.84-0.92) ($P = .02$ for interaction) for BMI at ages 25 to 34 years; difference in associations were also found for in situ (HR, 0.81; 95% CI, 0.76-0.86) and invasive breast cancer (HR, 0.88; 95% CI, 0.86-0.90; $P = .01$ for interaction) at 35 to 44 years (eTable 3 in the Supplement). The percentage of all breast cancers that were in situ did not appreciably vary by BMI, and women with higher BMI were more likely to have had a screening mammogram (eTable 4 in the Supplement).

The ER and/or PR status was known for 7812 cases, 7002 (89.6%) of which were invasive. We did not observe consistent significant differences in HRs for ER-positive vs ER-negative or PR-positive vs PR-negative breast cancer (eTable 5 in the Supplement). When considering ER and PR jointly, ER-positive and/or PR-positive breast cancer showed stronger associations with BMI at ages 18 to 24 years (eg, for ER-positive and PR-positive, HR, 0.75; 95% CI, 0.70-0.81) than did hormone receptor-negative breast cancer; however, the association was still significant for ER-negative and PR-negative breast cancer (HR, 0.85; 95% CI, 0.76-0.95) (eFigure 5 in the Supplement). Body mass index at older ages was not associated with hormone receptor-negative breast cancer risk. In analyses by intrinsic breast cancer subtype (Figure 3), the non-luminal (ER-negative and PR-negative) subtype was inversely associated with BMI at ages 18 to 24 (HR, 0.86; 95% CI, 0.77-0.96) and 45 to 54 years (HR, 0.90; 95% CI, 0.84-0.98), but not with BMI at ages 25 to 34 and 35 to 44 years. No association of BMI at 25 years or older with triple-negative breast cancer or at BMI of 35 years or older with ERBB2/HER2-enriched breast cancer was found.

Hazard ratios per 5.0-U difference in BMI were not significantly different between strata of most risk factors for breast cancer, including race/ethnicity (for BMI at ages 18 to 24 years: HR for black women, 0.84 [95% CI, 0.76-0.93]; HR for Asian women, 0.69 [95% CI, 0.40-1.18]; and HR for white women, 0.73 [95% CI, 0.70-0.77]; $P = .08$ for interaction) (eFigure 6 and eTable 6 in the Supplement). Hazard ratios were greater for never users compared with than ever users of oral contraceptives (at baseline for most studies) for BMI at ages 18 to 24 years (HR, 0.68 [95% CI, 0.61-0.76] vs 0.79 [95% CI, 0.75-0.83]; $P = .02$ for interaction) and ages 35 to 44 (HR, 0.81 [95% CI, 0.77-0.86] vs 0.88 [95% CI, 0.86-0.91]; $P = .009$ for interaction). The HR was also greater for nulliparous than parous women (HR, 0.79 [95% CI, 0.73-0.87] vs 0.88 [95% CI, 0.84-0.93]; $P = .03$ for interaction) for BMI at ages 25 to 34 years. Results were not materially affected in the sensitivity analyses (eTables 7-9 in the Supplement) except for those shown in Figure 1.

Discussion

In this large prospective analysis investigating the association between adiposity and breast cancer risk in premenopausal women, we analyzed relative risk by BMI in a larger number of categories than possible in previous studies, re-
vealing a 4.2-fold risk gradient between women who were underweight vs obese at ages 18 to 24 years and a 1.9- to 2.5-fold risk gradient between these BMI categories at later ages. We demonstrated that the inverse associations apply to the entire distribution of BMI, with risk variations evident even among women in the nonoverweight range of BMI.

Table. Characteristics at Study Recruitment of Women Included in the Analyses

| Characteristic                         | Participants, No. (BMI≥30.0, %) | Person-years of Follow-up, No. (%) | Cancer Cases, No. |
|----------------------------------------|----------------------------------|-----------------------------------|-------------------|
| BMI                                     |                                  |                                   |                   |
| 15.0-16.9                              | 2843                             | 29 293 (0.4)                      | 53                |
| 17.0-18.4                              | 20 245                           | 221 540 (3.1)                     | 442               |
| 18.5-24.9                              | 499 146                          | 4 901 964 (68.1)                  | 9356              |
| 25.0-29.9                              | 159 660                          | 1 375 769 (19.1)                  | 2257              |
| 30.0-34.9                              | 51 413                           | 442 769 (6.2)                     | 678               |
| 35.0-49.9                              | 25 285                           | 227 485 (3.2)                     | 296               |
| Age at entry, y                        |                                  |                                   |                   |
| ≥25                                    | 17 627 (9.2)                     | 211 220 (2.9)                     | 74                |
| 25-34                                  | 167 744 (8.9)                    | 2 585 847 (35.9)                  | 3657              |
| 35-44                                  | 366 893 (10.1)                   | 3 688 360 (51.2)                  | 7404              |
| ≥45                                    | 206 328 (11.1)                   | 713 394 (9.9)                     | 1947              |
| Age at menarche, y                     |                                  |                                   |                   |
| 7-11                                   | 141 899 (17.0)                   | 1 410 957 (19.6)                  | 2712              |
| 12-13                                  | 391 822 (9.7)                    | 3 849 467 (53.5)                  | 7117              |
| ≥14                                    | 195 180 (6.2)                    | 1 715 887 (23.8)                  | 2871              |
| Missing or no periods                  | 29 691 (9.1)                     | 222 509 (3.1)                     | 382               |
| Age at first birth, y                  |                                  |                                   |                   |
| <25                                    | 290 668 (11.2)                   | 2 630 694 (36.5)                  | 4186              |
| 25-34                                  | 273 023 (8.7)                    | 2 583 161 (35.9)                  | 5364              |
| ≥35                                    | 19 152 (9.5)                     | 1 348 363 (1.9)                   | 393               |
| Nulliparous                            | 121 920 (12.4)                   | 1 311 508 (18.2)                  | 2367              |
| Age or whether parous unknown          | 53 829 (6.7)                     | 538 621 (7.5)                     | 772               |
| No. of birthsc                         |                                  |                                   |                   |
| 1                                      | 128 760 (10.4)                   | 1 358 259 (25.2)                  | 2583              |
| 2                                      | 252 325 (9.4)                    | 2 213 928 (41.0)                  | 4356              |
| 3                                      | 188 633 (10.8)                   | 1 650 219 (30.6)                  | 2900              |
| Not known                              | 18 341 (6.5)                     | 178 049 (3.3)                     | 172               |
| Family history of breast cancer        |                                  |                                   |                   |
| No                                     | 556 203 (10.1)                   | 5 576 245 (77.5)                  | 9478              |
| Yes                                    | 75 299 (12.8)                    | 625 576 (8.7)                     | 2265              |
| Not known                              | 127 090 (8.4)                    | 997 000 (13.8)                    | 1339              |
| Race/ethnicity                         |                                  |                                   |                   |
| White                                  | 419 130 (10.0)                   | 4 437 300 (61.6)                  | 8437              |
| Black                                  | 52 903 (26.8)                    | 586 734 (8.2)                     | 1006              |
| Asian                                  | 26 214 (2.5)                     | 212 411 (3.0)                     | 235               |
| Other                                  | 7894 (13.7)                      | 89 276 (1.2)                      | 167               |
| Not known                              | 252 451 (7.5)                    | 1 873 100 (26.0)                  | 3237              |
| Birth cohort                           |                                  |                                   |                   |
| Before 1930                            | 23 849 (9.1)                     | 98 669 (1.4)                      | 178               |
| 1930-1939                              | 66 110 (7.7)                     | 655 904 (9.1)                     | 1306              |
| 1940-1949                              | 243 663 (8.4)                    | 1 878 359 (26.1)                  | 4088              |
| 1950-1959                              | 282 307 (10.9)                   | 2 983 715 (41.4)                  | 5305              |
| 1960-1969                              | 101 002 (13.7)                   | 1 183 177 (16.4)                  | 1970              |
| 1970-1979                              | 33 904 (11.2)                    | 341 589 (4.7)                     | 219               |
| 1980 or later                          | 7757 (8.1)                       | 57 407 (0.8)                      | 16                |
| All                                    | 758 592 (10.1)                   | 7 198 821 (100.0)                 | 13 082            |

Abbreviation: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared).

* Percentages have been rounded and may not total 100. Owing to rounding, person-years may not sum to the total.

Indicates at study entry or, if missing, most recent retrospectively reported weight.

Includes parous only.
Body mass index (BMI) is calculated as weight in kilograms divided by height in meters squared. Hazard ratios (HRs) were adjusted for attained age, cohort, year of birth, age at menarche, age at first birth, number of births, time since last birth, and family history of breast cancer as well as BMI at ages 18 to 24 years.

* Represents linear trend per 5 kg/m² (5.0-U) difference in BMI from 18.5 to 49.9.

The observed inverse associations are unlikely to be attributable to bias, given that they were present in multiple studies and across strata of birth cohort and risk factors for breast cancer. Too few women died during follow-up (3.3% of women with a BMI≥35.0 vs 1.7% with BMI of 18.5-24.9) to explain the inverse associations for death as a competing risk. Our results are also supported as causal rather than artifactual by a mendelian randomization study reporting genetically predicted BMI to be inversely associated with breast cancer.

The stronger inverse associations of risk with BMI at younger than older ages suggest that adiposity in young adulthood or earlier, if adiposity at approximately 20 years of age is a proxy marker for adiposity in childhood, is the critical factor. No cohorts in our collaboration had information on BMI.
Our estimated 12% to 23% reduction in premenopausal breast cancer risk per 5.0-U difference in BMI depending on age is substantially stronger than that from meta-analyses, which have reported 5% to 9% reductions among women overall without analysis by age at BMI, and a study reporting a 10% reduction using measured BMI at ages 16 to 19 years. We observed that associations of BMI and breast cancer risk did not depend on attained age. We found no previous analyses by premenopausal attained age, but risk reductions with increased early-life BMI have been reported to continue after menopause. The associations of BMI with risk also did not appear to be appreciably modified by risk factors for breast cancer later in life, with the possible exception of nulliparity and oral contraceptive use.

The stronger associations of BMI at ages 25 to 44 years for in situ than for invasive breast cancer might reflect type-specific etiology or the association for in situ cancer being in part attributable to an association of body size with breast screening attendance. However, we found no evidence for this association, given that percentages of in situ cancer were similar across BMI groups.

No previous analyses of hormone receptor status-specific breast cancer by BMI assessed at different premenopausal ages have been performed, to our knowledge. We found that hormone receptor–positive breast cancer was associated with BMI at all ages and that hormone receptor–negative breast cancer overall was associated with BMI at ages 18 to 24 years, but not consistently associated with BMI at later ages; meta-analyses of ER- and PR-negative tumors have found no association, based on age at recruitment. The absence of an association of triple-negative breast cancer with BMI at 25 years or older in our analysis is contrary to previous reports indicating an increased risk of this tumor type with obesity; however, these reports were based on case-control studies and a pooled analysis of women younger than 50 years based on studies of mixed design and therefore are subject to potential biases that are of less concern in prospective cohorts. We observed that ERBB2/HER2–enriched breast cancer was associated with BMI at 35 years or younger but not at later ages; the Nurses’ Health Study, included in this analysis, previously reported a strong association with BMI at 18 years of age, but we are not aware of studies investigating the association with later premenopausal ages.

Obesity has many adverse effects on general health, and we do not advocate weight gain as a preventative measure against premenopausal breast cancer. However, understanding the mechanistic action underlying the inverse association of premenopausal adiposity with breast cancer risk could potentially identify modifiable pathways. Because the association with BMI at ages 18 to 24 years is significant for ER-positive and ER-negative tumors, hormonal and nonhormonal mechanisms might be involved. Breast tissue is particularly susceptible to carcinogens between menarche and first childbirth, and the extent of this susceptibility may be influenced by childhood adiposity. Increased adiposity has a strong association with early pubertal onset but also slower pubertal tempo, including slower peak growth, and rapid adolescent growth has been associated with increased breast cancer risk.

at younger than 18 years, but published analyses of subjective body size compared with peers at these ages have found strong inverse associations with premenopausal and postmenopausal breast cancer risk.

Body mass index (BMI) is calculated as weight in kilograms divided by height in meters squared. The luminal A-like subtype includes estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, and ERBB2/HER2-negative tumors; luminal B-like subtype, all ER-positive and/or PR-positive tumors that are not luminal A-like (subtypes luminal B-like ERBB2/HER2-negative and luminal B-like ERBB2/HER2-positive); and nonluminal subtype, all ER-negative, PR-negative, and ERBB2/HER2-positive tumors. Our estimated 12% to 23% reduction in premenopausal breast cancer risk per 5.0-U difference in BMI depending on age is substantially stronger than that from meta-analyses, which have reported 5% to 9% reductions among women overall without analysis by age at BMI, and a study reporting a 10% reduction using measured BMI at ages 16 to 19 years. We observed that associations of BMI and breast cancer risk did not depend on attained age. We found no previous analyses by premenopausal attained age, but risk reductions with increased early-life BMI have been reported to continue after menopause. The associations of BMI with risk also did not appear to be appreciably modified by risk factors for breast cancer later in life, with the possible exception of nulliparity and oral contraceptive use.

The stronger associations of BMI at ages 25 to 44 years for in situ than for invasive breast cancer might reflect type-specific etiology or the association for in situ cancer being in part attributable to an association of body size with breast screening attendance. However, we found no evidence for this association, given that percentages of in situ cancer were similar across BMI groups.

No previous analyses of hormone receptor status-specific breast cancer by BMI assessed at different premenopausal ages have been performed, to our knowledge. We found that hormone receptor–positive breast cancer was associated with BMI at all ages and that hormone receptor–negative breast cancer overall was associated with BMI at ages 18 to 24 years, but not consistently associated with BMI at later ages; meta-analyses of ER- and PR-negative tumors have found no association, based on age at recruitment. The absence of an association of triple-negative breast cancer with BMI at 25 years or older in our analysis is contrary to previous reports indicating an increased risk of this tumor type with obesity; however, these reports were based on case-control studies and a pooled analysis of women younger than 50 years based on studies of mixed design and therefore are subject to potential biases that are of less concern in prospective cohorts. We observed that ERBB2/HER2–enriched breast cancer was associated with BMI at 35 years or younger but not at later ages; the Nurses’ Health Study, included in this analysis, previously reported a strong association with BMI at 18 years of age, but we are not aware of studies investigating the association with later premenopausal ages.

Obesity has many adverse effects on general health, and we do not advocate weight gain as a preventative measure against premenopausal breast cancer. However, understanding the mechanistic action underlying the inverse association of premenopausal adiposity with breast cancer risk could potentially identify modifiable pathways. Because the association with BMI at ages 18 to 24 years is significant for ER-positive and ER-negative tumors, hormonal and nonhormonal mechanisms might be involved. Breast tissue is particularly susceptible to carcinogens between menarche and first childbirth, and the extent of this susceptibility may be influenced by childhood adiposity. Increased adiposity has a strong association with early pubertal onset but also slower pubertal tempo, including slower peak growth, and rapid adolescent growth has been associated with increased breast cancer risk.
cancer risk. The estrogenic effects of being overweight in childhood, when adipose tissue is the major site of estrogen release, have been proposed to induce early breast differentiation or to increase the expression of tumor suppressor genes. Being underweight during adolescence, in contrast, might result in immature differentiation due to lack of breast fat and/or low levels of ovarian hormones during breast development.

Early-adulthood adiposity is associated with intermediate markers of breast cancer risk, such as benign breast disease, mammographic density, and insulin-like growth factor I levels. Greater mammographic density has a positive association with breast cancer risk, and a more endomorphic somatotype in childhood and early adulthood is associated with lower mammographic density throughout adulthood. In the Nurses’ Health Study, 82% of the association of BMI at 18 years of age with breast cancer risk was explained by mammographic density, and breast density may be an intermediate factor in the biological pathway for breast cancer development. However, the mechanism of how density affects risk is not well understood, and the amount of nondense (ie, fatty) tissue, with which BMI is strongly correlated, is also inversely associated with breast cancer risk, independently of percentage density.

Early-life body size might also affect long-term insulin-like growth factor I levels implicated in breast cancer risk, given that plasma insulin-like growth factor I levels at ages 32 to 70 years were reported to be 14% lower in women who were overweight compared with those who were lean at age 18 years.

The inverse association of BMI in premenopausal women 25 years or older with predominantly hormone receptor-positive rather than hormone receptor-negative breast cancer implies a hormonal mechanism. Estrogen synthesis, through the aromatase enzyme in subcutaneous fat, represents about 5% of total estradiol synthesis in premenopausal women, but with extreme obesity, negative feedback in the hypothalamic-pituitary-axis can lead to switch off of normal ovarian function and be reflected in amenorrhea. Irregular menstrual or fewer ovulatory cycles have therefore been suggested as possible explanations for the inverse association, but this suggestion has not been supported by studies that could adjust for menstrual cycle pattern. However, BMI-related differences in sex-hormone profile may contribute to the inverse association of BMI and breast cancer risk. A study reported that premenopausal women with higher BMI had lower estradiol, total testosterone, sex hormone-binding globulin, and progesterone levels but greater free testosterone levels than premenopausal women with lower BMI. Positive associations of premenopausal breast cancer risk have been reported with estradiol and testosterone levels, possibly stronger for ER-positive and/or PR-positive breast cancer, but studies have been inconsistent. Studies investigating endogenous progesterone levels, however, have not found associations with breast cancer risk. Circulating levels of leptin, a peptide hormone produced primarily by adipocytes that is overexpressed in breast cancer, were also associated with reduced premenopausal breast cancer risk in a prospective study, although not independently from BMI.

Strengths and Limitations

The strengths of this collaboration are its large number of cases, providing precise estimates of relative risk by age at adiposity and allowing for stratified and breast cancer subtype-specific analyses. All contributing studies were prospective, and most had multiple follow-up rounds, facilitating determination of menopausal status and time-updated covariate information.

However, the use of BMI has its limitations in that women with the same BMI can have different body fat distributions and overall body fat levels. Body mass index was recalled for early adulthood, but a good correlation (r = 0.87) has been reported between recalled and measured weight at 18 years of age. Current weight was usually self-reported, but in the Sister Study, 66% of women accurately reported their current weight within 1.35 kg, and underweight women tended to overreport and obese women tended to underreport, although rarely by more than 10%. If such misclassification applied to all studies, we might have slightly overestimated the trends but not to a sufficient degree to account for them fully. On the other hand, random misclassification would have led to attenuated effect sizes. Study-specific differences in method of assessment and cut points for hormone receptor and ERBB2/HER2 status of breast cancer, given that these data were frequently obtained from medical records, may have led to differential classification of the tumor types between studies, potentially leading to underestimation of relative risks. More than 1000 breast cancer cases occurred in black women, allowing for stable estimation of relative risks in that population; results were similar to results from white women. However, we had insufficient statistical power to address the hypothesis that associations might be weaker or absent in Asian populations.

Conclusions

The results of our study suggest that increased BMI is inversely associated with the risk of breast cancer diagnosis before menopause, to a greater magnitude than suggested in previous analyses, and with the strongest associations for BMI at young ages. The association with BMI in early adulthood is universal across strata of other risk factors and across breast cancer subtypes. Understanding the biological mechanism underlying this association could have important implications for breast cancer prevention.
Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women

Original Investigation Research

371(9612):569-578.

cancer: a systematic review and meta-analysis of

References

Zwahlen M. Body-mass index and incidence of

3

Clin

4

breast cancer risk and outcome: mechanistic

jamaoncology.com

Global cancer in women: burden and trends.

REFERENCES

Facilitating this collaboration.

the National Cancer Institute Cohort Consortium for

Yu, MPH, Slone Epidemiology Center at Boston

MD, MS, UPMC Hillman Cancer Center, University of

Technologists, St Paul, Minnesota; Renwei Wang,

Korean women: a nationwide cohort study.

Int J Obes (Lond)

2018;40(3):524-530.

Keinan-Boker L, Levine H, Derazene E,

Molina-Hazan V, Kark JD. Measured adolescent

body mass index and adult breast cancer in a cohort of 951 480 women.

Breast Cancer Res Treat 2016;158(1):157-167.

Munsell MF, Sprague BL, Berry DA, Chisholm G,

Trentah-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestogen use and hormone status.

Epidemiol Rev. 2014;36:114-136.

Amadou A, Ferrari P, Muxwong R, et al.

Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dosee-response meta-analysis. Obes Rev. 2013;14(8):665-678.

Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status—a meta-analysis. Int J Cancer. 2009;124(3):698-712.

Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137(1):307-314.

Yang XR, Chang-Claude J, Goode EL, et al.

Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250-262.

Nichols HB, Schomerak MJ, Wright LB, et al.
The Premenopausal Breast Cancer Collaboration: a pooling project of studies participating in the

National Cancer Institute Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2017;26(9):1360-1369.

When Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies Lancet. 2004;363(9403):157-163.

Cox DR. Regression models and life-tables. J Stat Soc [Ser A]. 1972;34(2):187-220.

Stukel TA, Demidenko E, Dykes J, Karagas MR. Two-stage methods for the analysis of pooled data. Stat Med. 2001;20(14):2115-2130.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-1558.

Harrell F. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer; 2001.

Buse A. The likelihood ratio, Wald, and Lagrange multiplier tests—an expository note. Am Stat. 1982;36(3, pt 1):153-157.

Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics. 1995;51(2):524-532.

StataCorp, ed. Stata Statistical Software: Release 4. College Station, Texas: StataCorp LP, 2015.

Guo Y, Warren Andersson S, Shu XO, et al. Genetically predicted body mass index and breast cancer risk: mendelian randomization analyses of data from 145 000 women of European descent. PLoS Med. 2016;13(8):e1002015.

Afshin A, Forouzanfar MH, Reitsma MB, et al. GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(13):12-27.

Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev. 1993;4(5):567-571.

Martí-Henneberg C, Vizmanos B. The duration of puberty in girls is related to the timing of its onset. J Pediatr. 1997;131(4):618-621.

Vizmanos B, Martí-Henneberg C, Clavillé R, Moreno A, Fernández-Ballart J. Age of pubertal onset affects the intensity and duration of pubertal growth peak but not final height. Am J Hum Biol. 2001;13(3):409-416.

Berkey CS, Frazier AL, Gardner JD, Colditz GA. Adolescence and breast carcinoma risk. Cancer. 1999;85(11):2400-2409.

Hilakivi-Clarke L, Forsen T, Eriksson JG, et al. Tallness and overweight during childhood have opposing effects on breast cancer risk. Br J Cancer. 2001;85(11):1680-1684.

Suzuki R, Saji S, Toi M. Impact of body mass index on breast cancer in accordance with the life-stage of women. Front Oncol. 2012;2:123.

Berkey CS, Rosner B, Tamimi RM, et al. Body size from birth through adolescence in relation to risk of benign breast disease in young women. Breast Cancer Res Treat. 2017;162(1):139-149.

Yochum L, Tamimi RM, Hankinson SE. Birthweight, early life body size and adult mammographic density: a review of epidemiologic studies. Cancer Causes Control. 2014;25(10):1247-1259.

Poole EM, Tworoger SS, Hankinson SE, Schernhammer ES, Pollak MN, Baer HJ. Body size in

Downloaded From:  by a The Bodleian Libraries of the University of Oxford User  on 11/16/2018

JAMA Oncology November 2018 Volume 4, Number 11 9/10

jamaoncology.com

(1950-1979) with respect to body mass index and age: a population based prospective cohort study on breast cancer in Swedish women. Acta Oncol. 2000;39(5):509-517.

Gudbjartsson DF, Manolescu A, Hjartardóttir A, et al. Variation in body mass index in 195 countries during the past 50 years: a multinational study. Lancet Diabetes Endocrinol. 2017;5(10):760-773.

Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152(6):514-527.

Warner ET, Hu R, Collins LC, et al. Height and body size in childhood, adolescence, and young adulthood and breast cancer risk according to molecular subtype in the Nurses’ Health Studies. Cancer Prev Res (Phila). 2016;9(9):732-738.

Baer HJ, Tworoger SS, Hankinson SE, Willett WC. Body fatness at young ages and risk of breast cancer throughout life. Am J Epidemiol. 2010;171(11):1183-1194.

Oh H, Boeke EE, Tamimi RM, et al. The interaction between early-life body size and physical activity on risk of breast cancer. Int J Cancer. 2015;137(3):571-581.

Michels KB, Terry KL, Willett WC. Longitudinal study on the role of body size in premenopausal breast cancer. Arch Intern Med. 2006;166(21):2395-2402.

Palmer JR, Adams-Campbell LL, Boggs DA, Wise LA, Rosenberg L. A prospective study of body size and breast cancer in black women. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1795-1802.

Lee KR, Hwang IC, Jung J, Song SE. Waist circumference and risk of breast cancer in Korean women: a nationwide cohort study. Int J Cancer. 2018;142(8):1554-1559.

Chen MJ, Wu YY, Chen AM, et al. Body mass index and breast cancer: analysis of a nation-wide population-based prospective cohort study on 1 393 985 Taiwanese women. Int J Obes (Lond). 2016;40(3):524-530.

Reinehr AG, Tyson M, Egger M, Heller RF, Zwiwel M. Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-578.

Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti Irani A. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS One. 2012;7(12):e54146.

Kyrgiou M, Kalliath I, Markozanannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017;356:j477.

van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152(6):514-527.

Zwahlen M. Body-mass index and incidence of breast cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-578.

Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti Irani A. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS One. 2012;7(12):e54146.
early life and adult levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3. Am J Epidemiol. 2011;174(6):642-651.

40. Pettersson A, Tamimi RM. Breast fat and breast cancer. Breast Cancer Res Treat. 2012;135(1):321-323.

41. Rice MS, Bertrand KA, VanderWeele TJ, et al. Mammographic density and breast cancer risk: a mediation analysis. Breast Cancer Res. 2016;18(1):94.

42. Key TJ, Appleby PN, Reeves G, Roddam AW; Endogenous Hormones and Breast Cancer Collaborative Group. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2013;14(10):1009-1019.

43. Eliassen AH, Mismar SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 2010;92(19):1451-1457.

44. Fortner RT, Eliassen AH, Spiegelman D, Willett WC, Barbieri RL, Hankinson SE. Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses’ Health Study II. Breast Cancer Res. 2013;15(2):R19.

45. Tworoger SS, Eliassen AH, Mismar SA, et al. Birthweight and body size throughout life in relation to sex hormones and prolactin concentrations in premenopausal women. Cancer Epidemiol Biomarkers Prev. 2006;15(12):2494-2501.

46. Key TJ, Appleby PN, Reeves G, et al; Endogenous Hormones and Breast Cancer Collaborative Group. Sex hormones and breast cancer risk in premenopausal women: collaborative reanalysis of seven prospective studies. Lancet Oncol.2013;14(10):1009-1019.

47. Walker K, Bratton DJ, Frost C. Premenopausal endogenous oestrogen levels and breast cancer risk: a meta-analysis. Br J Cancer. 2011;105(9):1451-1457.

48. Troy LM, Hunter DJ, Manson JE, Colditz GA, Stampfer MJ, Willett WC. The validity of recalled weight among younger women. Int J Obes. 1995;19(8):570-572.

49. Lin CJ, DeRoo LA, Jacobs SR, Sandler DP. Accuracy and reliability of self-reported weight and height in the Sister Study. Public Health Nutr. 2012;15(6):989-999.

50. Wada K, Nagata C, Tamakoshi A, et al; Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Body mass index and breast cancer risk in Japan: a pooled analysis of eight population-based cohort studies. Ann Oncol. 2014;25(2):519-524.